A5079826931- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
- Ferroptosis and cancer prognosis
- Pancreatic and Hepatic Oncology Research
- Cancer Genomics and Diagnostics
- Melanoma and MAPK Pathways
- Cutaneous Melanoma Detection and Management
- Genital Health and Disease
- Immune cells in cancer
- vaccines and immunoinformatics approaches
- Histone Deacetylase Inhibitors Research
- Adipose Tissue and Metabolism
- interferon and immune responses
- CAR-T cell therapy research
- Monoclonal and Polyclonal Antibodies Research
- Meta-analysis and systematic reviews
Semmelweis University
2022-2024
HUN-REN Research Centre for Natural Sciences
2023-2024
Immune-checkpoint inhibitors show promising effects in the treatment of multiple tumor types. Biomarkers are biological indicators used to select patients for a systemic anticancer treatment, but there only few clinically useful biomarkers such as PD-L1 expression and mutational burden, which can be predict immunotherapy response. In this study, we established database consisting both gene clinical data identify response anti-PD-1, anti-PD-L1, anti-CTLA-4 immunotherapies. A GEO screening was...
We developed a human melanoma model using the HT168-M1 cell line to induce IFN-α2 resistance in vitro (HT168-M1res), which was proven be maintained vivo SCID mice. Comparing mRNA profile of cultured HT168-M1res cells its sensitive counterpart, we found 79 differentially expressed genes (DEGs). that only 13-gene core DEGs stable and 4-gene vivo. Using an silico cohort IFN-treated tissues, validated 9-gene DEGs. Furthermore, immune checkpoint inhibitor (ICI)-treated tested predictive power for...
Malignant melanoma is a difficult-to-treat skin cancer with increasing incidence worldwide. Although type-I interferon (IFN) no longer part of guidelines, several patients are treated at some point the disease, potentially affecting its genetic progression. We run genome-wide copy number variation (CNV) analysis on previously IFN-treated (n = 17) and control 11) visceral metastases patients. Results were completed data from TCGA MM500 databases. identified metastasis- brain...
<h3>Background</h3> Immune checkpoint inhibitors, such as anti-PD-1, have transformed cancer therapy in the last decade. Yet, questions persist regarding their efficacy and pose ongoing challenges. Identifying more robust biomarkers is crucial immuno-oncology, iterative process between silico discovery experimental studies emphasizes of most suitable therapies for patients. Our aim was to pinpoint druggable, predictive resistance immune inhibitors by leveraging publicly available...
<h3>Background</h3> Meta-analyses are cornerstone tools in clinical research, enabling robust conclusions by synthesizing findings from multiple studies. We present a novel, web-based platform specifically designed to expedite and simplify the meta-analysis process for epidemiological trials. <h3>Methods</h3> This user-friendly portal integrates essential statistical models (random fixed effects) offers suite of informative visualizations. The underlying computational framework utilizes...
<h3>Background</h3> Blood-based biomarkers are extremely helpful for monitoring treatment response due to their non-invasiveness, easy sample collection and processing, cost-efficiency. Many blood markers assay platforms approved diagnostic, prognostic, predictive evaluation of diseases. However, none evaluating patient immune checkpoint inhibitors (ICIs) in cancer. Our goal was identify genes expressed that associated with immunotherapy resistance cancer patients. <h3>Methods</h3> We...
Abstract Background. Immune-checkpoint inhibitors can be administered in multiple solid tumor types. Currently available biomarkers, like the expression of PD-L1 or mutational burden, miss a significant proportion patients who could benefit from therapy. Our goal was to set up database consisting both gene and clinical response data uncover most biomarkers anti-PD-1, anti-PD-L1, anti-CTLA-4 immunotherapies. Methods. The GEO repository screened identify datasets with simultaneously...